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Progress in the method of simulated moving bed (SMB) technology and some important achieve-
ments in separation of specific classes of racemic compounds of therapeutic interest are reported
in the Part I of this review. Part II describes novel methods of SMB technology. Complex technolo-
gies, such as the combination of SMB and biocatalytic reactions, and SMB with crystallization pro-
cess, are presented. VariCol variant of SMB, and its application in the separation of the racemic
mixtures of commercial and academic interest are discussed. In the conclusive section, com-
ments are given concerning the economic dimension and the market of enantiomerically pure
compounds.
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1. Introduction
The huge success of “classic” SMB in the separation of com-
mercially important racemic mixtures has prompted even
more effective resolution methods in the continuous mode
and on the large scale. First, the separation capacity has
been improved by introducing the VariCol process, a vari-
ant of SMB, then improvements of in-process monitoring of
SMB that enable its coupling to crystallization process, and
to parallel chemical transformations, biocatalytic processes
in particular.
2. Examples of complex variants of SMB technology
2.1. In-process control of SMB separation
This aspect of SMB technology, recently improved by an
automated on-line enantiomeric analysis system comprising
an analytical HPLC set-up with two UV detectors sharing
the same light source, has been employed to monitor the
internal composition profile, Fig. 1.1
The feasibility and effectiveness of this on-line enantiomeric
monitoring scheme were assessed experimentally on the
separation of racemic Troger’s base (1), Fig. 2. Complete
separation was achieved on Chiralpak AD as stationary
phase and methanol as eluent.
Using a sampling interface placed between two SMB col-
umns, effluent samples are directed into a high-efficiency
analytical column at a sampling rate faster than the overall
dynamics of the preparative unit to complete on-line enan-
tiomeric analysis of the composition profile. The other UV
detector is placed in the SMB loop before the fraction col-
lector to provide instantaneous measurement of the total
enantiomeric concentration, Fig. 1. It was found that robust
monitoring of the concentration profiles of the individual
enantiomers is best achieved when the enantiomeric purity
obtained from the peak areas of the on-line enantiomer
analysis chromatograms is combined with the on-line UV
measurement of total enantiomeric concentration. The ac-
curacy and robustness of the proposed on-line enanti-
omeric monitoring system open up promising perspectives
for in-process control and dynamic optimization of the
SMB.
As for any SMB process, in this case the adsorbtion iso-
therms were first determined. As already discussed in Part I,
the operating conditions of chiral SMB process cannot be
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F i g. 1 – Schematic diagram of the on-line chiral monitoring
system. The main equipment comprises six-port two-position
valve, an analytical HPLC column, one HPLC pump, and two UV
detectors. The set-up is fully automated
S l i k a 2 – Shematski dijagram nadzornog sustava “on-line”.
Glavna oprema sastoji se od šest ulaza, dva ventila, analitièke
HPLC-kolone, HPLC-pumpe i dva UV-detektora. Postrojenje je pot-
puno automatizirano
properly determined without knowledge of the competitive
isotherms of the two enantiomers.2–6 The isotherms of the
enantiomers of Troger’s base were estimated by implying
the inverse method to the band profiles of the racemic mix-
ture obtained both in linear and overloaded eluation mo-
des,7 without measuring single component chromatograms.
This last condition allows development of the SMB process
without having standards of the pure enantiomers, an im-
portant condition in developing separation method of no-
vel racemates, previously unresolved by any available tech-
nique.
The inversed method of isotherm determination7 is becom-
ing popular as a quick procedure for the estimation of the
competitive isotherms necessary for designing SMB separa-
tions.8–10
2.2. The combined SMB-crystallization process
Most often enantiomers have
to be delivered as a powder
after SMB separation and
evaporation of the solvent. In
some cases, the downstream
crystallization step may be
viewed as a final polishing
step where the purity achi-
eved in the SMB is further
enriched.
Crystallization can be effec-
tively exploited by coupling
SMB and crystallization, as
proposed by several resear-
chers in the last few
years.11–14 A schematic dia-
gram of the combined pro-
cess is shown in Fig. 3, where
the SMB unit is followed by
two crystallizers for the ex-
tract and the raffinate streams,
which are at a purity below
process specifications but
above that of the eutectic formed by the two enan-
tiomers.11 In the crystallizers the pure enantiomers are pre-
cipitated, typically by evaporative crystallization, and with-
drawn, whereas the mother liquors that contain still both
enantiomers are recycled back to SMB together with the
evaporated solvent. The key idea behind this concept is
that, as the purity in the SMB decreases, the performance
parameters such as productivity and solvent consumption
improve, i. e. there is a net positive effect.
A multi-objective optimization study on the separation of
Troger’s base enantiomers in a combined process was car-
ried out based on experimental data on the absorption iso-
therms, the solubility of two enantiomers in ethanol, on a
detailed SMB model, and on a simplified model of the
crystallizers.11 With the aim of achieving maximum
throughput and minimum solvent evaporation, it was
shown that the optimal purity reached in the SMB in this
case was about 97 %, as lower purities would imply an ex-
cessively large mother liquor recycling.
Another example of the combined SMB-crystallization pro-
cess is found in production of optically pure ketamine.
S-Ketamine (2), 2-methylamino-2-(2-chlorophenyl)-cyclo-
hexanone. Ketamine (Ketaset(R)) is commercially available
as a racemate. It is a dissociate anesthetic agent that has
been widely used in clinical practice.15,16
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F i g. 2 – Racemic and (+)-form of Troger’s base (1)
S l i k a 2 – Racemièni i (+)-oblik Trogerove baze (1)
F i g. 3 – The combined SMB-crystallization process, where racemates as well as the pure enantio-
mers are fed and withdrawn, respectively, as solid material
S l i k a 3 – Kombinirani SMB i kristalizacijski proces, u kojem se racemat dodaje i èisti enantiomeri
odvode kao krutina
S-Ketamine is four times more potent in analgesia than
R-ketamine.16 Ketamine resolution has been reached in
commercial applications via diastereomeric salts,17,18 which
is one of the most traditional and least effective techniques
in the field of enantioseparation. A paper by Santos et al.,19
describes the continuous enantioseparation of ketamine in
a semipreparative scale SMB unit, using microcrystalline
cellulose triacetate (MCTA) as a chiral filling, providing a
suitable separation of the two enantiomers with virtually
100 % optical purity. A limitation, however, is the low pro-
ductivity of the process in the laboratory unit, around 0.15
to 0.5 g d–1.
Recent study has enabled the introduction of a hybrid pro-
cess consisting of continuous chromatography and crystalli-
zation to acquire high purity enantiomers with high pro-
ductivity.20 In this work, the theoretical behavior of SMB
units in separation of racemic Ketamine was analyzed tak-
ing into account the non-linearity of adsorption isotherms,
and non-homogeneity of packing columns. Experimental
operating points were selected aiming at the higher purity
of the S-enantiomer in the raffinate stream. The results ob-
tained showed purities above 99.5 % for S-ketamine in the
raffinate stream and above 97.7 % for R-ketamine in the ex-
tract stream.
2.3. Simulated moving bed reactor (SMBR)
The basic operating concept of an SMBR is analogous to
that of an SMB, Fig. 4. The enzyme is simply added
throughout the SMB unit, either to the solid phase (SP) in
immobilized form or to the mobile phase in soluble form.
Consequently, the starting materials can be continuously
converted in all sections of the SMBR. Consider a thermo-
dynamically limited reaction of the substrate S to the prod-
ucts P1 and P2. Species S is added to the SMBR in the feed
flow and is enzymatically converted to P1 and P2. Species P1
and P2 are separated from each other due to their different
adsorption behavior. This separation prevents the back-
ward reaction and enables complete conversion of S. Prod-
ucts P1 and P2 can be collected at the extract and raffinate
port, respectively, in high purity. Ideally, the retention of S
should be between that of P1 and P2.
2.4. Integrated operation of SMB
and biotransformations
This approach represents one of the most recent techno-
logical achievements for the high yield production of gener-
ics and fine chemicals. The rapid progress in biocatalysis,
identification and development of enzymes over the last
decade has enormously enlarged the chemical reaction
space that can be addressed not only in research applica-
tions, but also on industrial scale. Prominent examples stem
from the aldolase-catalyzed enantioselective carbon-car-
bon bond forming reactions, reactions catalyzed by isomer-
ising enzymes, and reactions that are kinetically controlled.
On the other hand, continuous chromatography concepts
such as the SMB technology have matured and are increas-
ingly realized on industrial scale for the efficient separation
of difficult compound mixtures – including enantiomers –
with unprecedented efficiency. It was recently proposed21
that coupling of the enzyme reactor and continuous chro-
matography is a very suitable and potentially generic pro-
cess concept to address the thermodynamic limitations of
promising biotransformations. This way, it should be possi-
ble to establish novel in situ product recovery processes of
unprecedented efficiency and selectivity that represent a
feasible way to recruit novel biocatalysts to the industrial
portfolio.
The question is posed whether by smartly coupling biocata-
lytic and process engineering steps we can design generic
processes that extend our arsenal of industrial biocatalysis.
One such area could be, for example, reactions whose yield
is limited by thermodynamic constraints, which might re-
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F i g. 4 – Simulated moving bed reactor (SMBR) with axial concentration profile of racemic substrate S and products P1 and P2
S l i k a 4 – Reaktor sa simuliranim pokretnim leÞajem (SMBR), s aksijalnim koncentracijskim profilom za racemièni supstrat S
i produkte P1 i P2
quire carrying out biocatalysis and product removal in one
unit. A prominent example is isomerase catalyzed reac-
tions. Usually, in such reactions the operator is left with a
potentially difficult process mixture of starting materials and
products. In order to achieve decent yields on an expensive
starting material, in reactions involving at least two starting
materials, the cheaper starting material is often applied in
large excess, adding to the difficulty of purification. Conse-
quently, such reactions have remained largely unexplored
on the preparative level.
Removal of the product from the reactor immediately or
shortly after its formation can be achieved by separating the
compound mixture in a continuous chromatograph, re-
moving the product, and returning the remainder of the
starting material to the reactor, Fig. 5. Depending on the
type of reaction, both operations could be carried out in
one reactor. Chromatography’s high resolution power pro-
vides a unique opportunity to accommodate the fact that
biocatalysts frequently do not change the physico-chemical
properties of a molecule by much, usually rendering work-
up of mixtures difficult. Furthermore, continuous chroma-
tography considerably reduces eluent consumption and
product dilution compared to traditional batch chromatog-
raphy schemes, making it a much more attractive proce-
dure.22–26
The few realized model processes combining biotransfor-
mation and SMB technology are almost exclusively based
on the SMBR concept, with enzymatic reactions leading to
at least two species, unreacted substrate and product, Table
1.27 In earlier works, the SMBR was investigated as a two
zone SMBR without the zones for regenerating eluent and
solid phase.28–30 Regeneration of the solid phase was ac-
complished by decoupling the last column of the extract
zone and eluting the strongly adsorbed compound with
fresh eluent. It was shown that the applied concept re-
quired only 34–72 % of the amount of enzyme needed in a
corresponding conventional batch reactor of the same pro-
ductivity.30 This concept was further developed into a clo-
sed-loop four zone SMBR by Azevedo et al.31
a-Alkylcaprolactones. P. Keiser et al.32 have recently re-
ported preparative-scale SMB separation of biocatalytically
produced regioisomeric -alkylcaprolactones, Scheme 1.
Generally, the separation of enantiomerically pure, but re-
gioisomeric compounds by SMB is attractive if the process
leads to high-purity products in high yield with excellent
throughput and reduced solvent use. The main factors in-
fluencing method optimization were identified and the pa-
rameters of temperature, pressure, weak adsorption, se-
paration factor and robustness were examined with the aim
to resolve bottlenecks. Under optimized conditions, the
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F i g. 5 – Concept of an on-line coupling of continuous chro-
matography and biotransformation
S l i k a 5 – Koncept povezivanja kontinuirane kromatografije i
biotransformacije “on-line”
T a b l e 1 – Enzymatic transformations in combination with SMB separation21
T a b l i c a 1 – Enzimska transformacija u kombinaciji s odjeljivanjem SMB21
Enzyme
Enzim
Enzymatic reaction
Enzimska reakcija
EC number
EC-broj
D-xylose isomerase
D-ksiloza-izomeraza
5.3.1.5
D-tagatose-3-epimerase
D-tagatoza-3-epimeraza
5.1.3.X
amino acid racemase
aminokiselinska racemaza
5.1.1.10
pyruvat-dependent aldolase
aldolaza ovisna o piruvatu
4.1.3.3.
glycin-dependent aldolase
aldolaza ovisna o glicinu
4.1.2.5.
productivity of the process in Scheme 1 was 260 g kg–1 sta-
tionary phase/day) of pure regioisomers and the solvent
consumption was 36.3 L kg–1 feed.
2.5. SMB combined with racemization
of the “wrong enantiomer”
The following example belongs to one of the most thor-
oughly investigated applications of SMB technology on the
large-scale.
Sertralin (3), (1S,4S)-1-methylamino-4-(34-dichlorophe-
nyl)tetrahydronaphthalene. Sertralin hydrochloride (Zo-
loft®) is an inhibitor of serotonine reuptake, and is an
important pharmaceutical agent for the treatment of de-
pression as well as dependency- and other anxiety-related
disorders.26,33
The structure of Sertralin is characterized by two stereo-
genic centers with absolute 1S,4S-configuration, and rela-
tive cis configuration. Due to two stereogenic centers cis
and trans racemates are conceivable, often named syn- and
anti diastereomers, and therefore diastereo- and enantiose-
lectivity are required in the specific synthetic steps.
The research of a technology for cost-effective production
of 4S-tetralone, Scheme 2, the key intermediate on the
route to Sertralin was shifted to a continuous chroma-
tographic separation of enantiomers based on SMB tech-
nology.27,28,34,35 Investment in SMB technology led to a
commercial route to Sertralin that increased throughput by
eliminating the processing of the “wrong” 4R-tetralone
through the entire process.29,36 This is in accord with the
general rule for the synthesis of chiral compounds in the
enantiomerically pure form; if you have to undertake sepa-
ration of enantiomers on the route, then do it as early as
possible. Research at Pfizer Inc. culminated in the process
depicted in Scheme 2. Crucial for the success of this process
proved fast, base-catalyzed racemization of the “wrong”
4R-enantiomer in the extract, and feed of racemtae back to
SMB unit. Most important operating parameters for pilot
scale performance are given in Table 1; impressive is the al-
most 100 % recovery of the target 4S-enantiomer.
T a b l e 2 – Pilot-scale operating parameters and perform-
ance for SMB separation of rac-Tetralone36
T a b l i c a 2 – Operacijski parametri na pilotnoj skali i radni uèi-
nak SMB odjeljivanja rac-Tetralona36
column
kolona
amylose (3-chloro-4-methyl-
phenylcarbamate)
amiloza (3-klor-4-metil-
fenilkarbamat)
mobile phase, y
pokretna faza, y
yMeCN/MeOH = 9 : 1
number of columns, N
broj kolona, N
6
column length, l
duljina kolone, l
9.9 cm
column diameter, d
promjer kolone, d
4.8 cm
feed mass concentration, g
masena koncentracija dotoka, g
30 g L–1
volume flow rate, Q
obujamski protok, Q
37 mL min–1
pressure, p
tlak, p
25 bar
(4S) tetralone, e.e.
(4S) tetralon, e.e.
99.7 %
(4S) tetralone recovery, Y
(4S) obnavljanje tetralona, Y
98.4 %
productivity, P
produktivnost, P
371 kg kg–1 a–1
2.6. VariCol variant of SMB technology
VariCol represents simulated moving beds with non-con-
stant operating conditions. The main benefit of the VariCol
operation mode is that it allows reducing the number of col-
umns with respect to the standard SMB operation without
sacrificing throughput and process specifications. In the
operation of the classical SMB unit, the column configura-
tion, i.e. the number of sections and the number of columns
per section is fixed prior to start-up. Once the unit is started,
the inlet and outlet ports are switched simultaneously, i.e. a
synchronous switch is implemented. Hence, in this mode of
operation, at any time the unit configuration is the one cho-
sen prior to start-up, where only an integer number of co-
lumns per section can be assigned. Let us consider as an
example a 6-column SMB unit. It is worth noting that using
six columns, with the limitation that a minimum of one co-
lumn is present in each section, ten different configurations
are possible, i.e. 1/2/2/1, 3/1/1/1… . In the case of an SMB
unit for the entire duration of the switch period the unit
configuration and the position of the inlet and outlet ports
remain the same. More freedom in choosing the unit con-
figuration is offered by the VariCol process, where each
port is switched independently of the others, i.e. port
switching is performed asynchronously as shown in Fig. 6.37
V. ŠUNJIÆ et al.: Recent Achievements in Simulated Moving Bed (SMB) Technology. Part II., Kem. Ind. 59 (9) 439–450 (2010) 443
S c h e m e 1 – SMB separation of regioisomiric lactones32
S h e m a 1 – SMB-razdvajanje regioizomernih laktona32
As readily observed, the switching period is subdivided into
four sub-intervals of duration 20 % or 30 % of the switch
time, and only one port is switched at the end of each sub-
interval. Therefore, during the four subintervals of the ex-
ample the unit configuration is first 1–2–1–2, then
1–2–2–1, then 2–1–2–1, finally 2–2–1–1, and then again
1–2–1–2 after exactly t. The average unit configuration can
be calculated, and turns out to be in this case
1.5–1.7–1.6–1.2, i.e. by asynchronously switching the
ports, the number of columns per section attains non-
integer values. This operation mode allows in principle for
infinite unit configurations and hence gives the possibility to
make the best use of the column for separation. The Vari-
Col has been experimentally demonstrated38,39 and com-
mercialized.40 Several theoretical and experimental studies
have shown that VariCol provides improved performance
compared to the classical SMB.41,42 VariCol, due to asyn-
chronous switching, is fairly complex to design and there
exist various methodologies discussed in the specialized ar-
ticles and chapters.43–45
Beside the VariCol process, there are ulterior modifications
of the original SMB process. Here we will be mentioned
two most promising variants;
– time-variable manipulation of flow rates, known as
PowerFeed process,46,47 and
– modulation of the feed mass concentration, known as
ModiCon process.48,49
PowerFeed process is characterized by the exchange of in-
ternal and external liquid flow-rates during the switching
period. This operation mode is referred to as PowerFeed.
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S c h e m e 2 – Production scheme for enantiomerically pure (1S,4S)-Sertralin
S h e m a 2 – Proizvodna shema za enantiomerno èisti (1S,4S)-Sertralin
F i g. 6 – Example of a VariCol switching strategy37
S l i k a 6 – Primjer strategije prespajanja VariCol37
Similar to theVaricol process, which allows for the asyn-
chronous movement of the ports, the PowerFeed process
exhibits more degrees of freedom than the classical SMB
process, and therefore allows more room for optimization.
Using an optimization technique based on a genetic algo-
rithm, three processes have been optimized for a few case
studies in order to determine their relative potentials. It is
found that PowerFeed and Varicol provide substantially
equivalent performances, which are however significantly
superior to those of the classical SMB process.46
The ModiCon process, instead, is based on the cyclic mo-
dulation of the feed concentration. It is demonstrated that
such a feed concentration gradient during the shifting cycle
can improve the performance of SMB process significant-
ly.49 The productivity and the product concentrations can
be increased while simultaneously the solvent consumption
can be decreased compared to the conventional SMB pro-
cess with constant feed parameters. This new concept of
modulation of feed mass concentration is based on exploi-
tation of thermodynamic equilibria, and requires, as it is the
case with VariCol and PoweFeed processes, a combined
approach to software development and experimental con-
trol of separation.
2.6.1. Recent separations by VariCol technology
In this section, examples of successful application of the
VariCol process will be presented.
SB-553261 racemate (4). The biological profile of this com-
pound is not cited in the available literature, still its separa-
tion on the multigram scale indicates preclinical or first-
-time-in-human (FTIH) trials with the preferred enantio-
mer.50,51
Under optimized conditions, the VariCol method proved
superior to SMB technology by 50 % in throughput and by
30 % in reduction of desorbent consumption, which is a
vast improvement.52
N-Boc-4-[p-chlorophenyl]-2-pyrrolidone (5). This compound
is a key racemic intermediate on the route to (S)-Baclofen),
4-amino-3-(4-chlorophenyl)butanoic acid. Racemic Bac-
lofen (Lioresal, Kemstro) is well known oral medication that
relaxes skeletal muscles. Chemically, baclofen is related to
-aminobutyric acid (GABA), a naturally occurring neuro-
transmitter in the brain. It is an agonist specific to mammal-
ian GABAB receptors.52,53 Baclofen is used for the treat-
ment of spastic movement, especially in instances of spinal
cord injury, spastic diplegia, and multiple sclerosis. Bac-
lofen has been shown to be as effective as diazepam in
uncomplicated alcohol withdrawal syndrome.54 A study
showed that it was effective in promoting alcohol absti-
nence in patients with severe liver cirrhosis.
Using adsorption equilibrium data, determination of the
optimal operational conditions for SMB separation of the
N-Boc-4-[p-chlorophenyl]-2-pyrrolidone enantiomers in a
semi-preparative scale VariCol unit is reported.55
This SMB unit was used to obtain high purity enantiomers
on a scale of 1 g d–1. The outlet streams were analyzed by an
online system that consisted of a UV-vis spectrophotomet-
ric unit, a polarimeter, and HPLC. Enantiomeric purities of
up to 97 % were obtained for the raffinate stream and up to
90 % for the extract stream.
SMB technology is claimed as the method of choice for
separation of protected amino acids.56 In view of their sim-
ple conversion to amino alcohols, and incorporation of the
latter in the mono- and bidentate ligands, this technology
opens the route to novel organometallic catalytic com-
plexes.
L-Methionine (6). L-Methionine is an important sulfur amino
acid in controlling nutrient metabolism and cell functions,57
and also prevents diabetes and diabetic complications.58
Particularly instructive application of SMB technology in
separation of racemic methionine uses an eremomycin
based-chiral stationary phase.59 This new CSP is based on
the macrocyclic glycopeptide eremomycin immobilized on
epoxy-activated silica. yMeOH/H O2 = 20:80 (0.1 mol L
–1
NaH2PO4) was used as the mobile phase. Separation was
realized under nonlinear conditions providing productivi-
ties around 15 g product per l g CSP per h for both enanti-
omers of 6. Column to column fluctuations were negligible
and long-term stability of the preparative stationary phase
was satisfactory according to the results of perturbation ex-
periments performed before and after long-term SMB runs.
(1S,2S)-Tetralol (7). (1S,2S)-1-isopropyl-2-(2-methoxyacetyl-
oxy)-2-(2-(3-benzimidazol-2-yl)-propionylamino-6-fluoro-
tetrahydronaphthalene. (1S,2S)-Tetralol (Mibefradil) is the
first Ca-channel blocker antagonist to appreciably antago-
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nize T-type Ca-channels, and one of the most effective anti-
hypertensive compounds.60 Due to easy availability of di-
astereomeric racemates from -naphthol,61 industrial sepa-
ration of biologically active (1S,2S)-enantiomer has gained
on importance, Scheme 3.
Chiral separation of racemic Tetralol by SMB was com-
pleted using a standard simulation package to predict the
effect of the operating variables on the process perfor-
mance. The experimental operation of the pilot plant SMB
unit Licosep 12–26 (Novasep, France) is carried out using
the chiral adsorbent Chiralpak AD with particle diameter dp
= 20 nm.62 To obtain real insight into operation of the SMB
unit Licosep 12-26 the mathematical model accounts for all
dead volumes inside of the SMB unit and time delay in shift-
ing of injection and withdrawal points. Experimental and
theoretical results based on the SMB model are compared
in terms of process performance parameters and internal
concentration profiles.
More recently, the basic data necessary for further develop-
ment of the production-scale processes using Chiralpak IA
columns were acquired.63 A broad range of solvents used as
components of mobile phases were tested and their influ-
ence on the separations evaluated. A satisfactory separation
considering further utilization of SMB was found for Propra-
nolol, Guaifenesin, and -Tetralol using the following mo-
bile phases yn-heptane/MeOH/EtOH (5:95:0.1) vol/vol), yn-heptane/EtOH
and yn-heptane/DCM (both in volume ratio 85:15), respectively.
Inverse size exclusion chromatography was implemented
to measure the porosity of the column using the set of poly-
styrene standards. The multicomponent adsorption equilib-
rium was characterized by linear Langmuir model for Tet-
ralol due to its limited solubility in selected mobile phases.
Table 3 gives a short, informative list of some active phar-
maceutical ingredients (APIs), which are not discussed in
more detail in this review, but separated in large quantities
for commercial purpose.
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S c h e m e 3 – Production scheme for enantiomerically pure (1S,2S)-tetralol
S h e m a 3 – Proizvodna shema za enantiomerno èisti (1S,2S)-tetralol
T a b l e 3 – Commercial APIs separated by SMB technology
T a b l i c a 3 – Komercijalni API razdvojeni tehnologijom SMB
Structure
Struktura
Trade name
Trgovaèko ime
CSP/solvent
CSP/otapalo
Column ID
ID kolone
Production/year
Proizvodnja/godina
Levetiracetam,
Leppra Chiralpak AD
n-hexane/EtOH
35–45 cm > 12 t/a
Citalopram,
Lexapro Chiralpak AD, and others
MeCN/EtOH
80 cm > 50 t/a
DOLE
Chiralcel OF
n-hexane/2-propanol
10 cm 130 kg
2.7. SMB separation of axially chiral compounds
Axially chiral compounds in optically pure form have gain-
ed enormous importance as bidentate ligands in orga-
nometallic catalytic complexes.64,65 Their separation from
racemates by crystallization of their salts is often hampered
by the absence of strong basic or acidic groups, or pure
crystallization properties. Therefore, chromatographic se-
parations, in particular SMB became methods of choice for
production of catalytic ligands in optically pure form. Out-
standing examples of effective SMB separation are BINOL
(8), the key intermediate on the route to BINAP, chiral
ligand with broad application in industrial processes,66,67
and BINAP-O, another precursor of BINAP and useful
ligand in enantioselective alkylations of arylaldehides.68
SMB technology is developed for separation of rac. BINOL,
on the route to enantiomerically pure (R)-(+)–BINAP, and
patents are claimed by Merck69 and GreatLakes/Monsan-
to70 companies.
We have recently claimed separation of BINAP-O on the
original, “Brush type” CSP, using SMB technology.71 This
technology enabled us to produce approx. 100 g of both
enantiomers with 99.9 % and 100 % e.e., respectively, Ta-
ble 4.
It is important to emphasize that after intensive screening of
the solvents, this process uses MeOH, one-component,
cheap and easily recyclable eluent.
3. Conclusive remarks, commercial
aspects of chiral drugs
New FDA regulations have had a major impact on the phar-
maceutical industry. The percentage of single-enantiomeric
drugs in the market increased from 10 % before the 1990s
to about 37 % in 2005, when the sale of single-enantio-
meric pharmaceutical products amounted to US$ 225 bil-
lion (2005 prices).72
Table 5 evidences the importance of chiral drugs in the op-
tically pure form for the global economy. In relation to the
volume of chiral drugs, it is interesting to consider the cur-
rent financial environment of the pharmaceutical industry
in terms of costs and R&D productivity. In 2006, only 18
new medical entities (NME) were approved by FDA, the
same number as in 2005; the decrease of approvals is a di-
rect result of reduced number of new drug applications.73
Analyses of the cost of an approved NME by the Boston
Consulting Group resulted in a figure of $881 million, in
good agreement with DiMasi et al. estimate of approx.
$800 million.74 The “Blockbuster business model” intro-
duced by pharmaceutical companies a few decades ago,
was focused on the development of high market-volume
drugs. However, the potential for the withdrawal of block-
buster drugs from the market due to safety reasons has be-
came a key vulnerability of this model.75
Considering all these data, the present delay in delivery and
marketing of NMEs is not surprising. Inventive biotech com-
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T a b l e 4 – SMB parameters for separation of BINAPO71
T a b l i c a 4 – Parametri SMB za separaciju BINAPO71
8 Columns (g of CSP)
8 kolona (g od CSP)
48 48
feed flow (mL min–1)
protok dotoka (mL min–1)
0.5 0.5
feed mass concentration (g L–1)
masena koncentracija dotoka (g L–1)
12.5 12.5
solid flow rate (mL min–1)
protok krutine (mL min–1)
0.63 0.66
raffinate flow rate (mL min–1)
protok rafinata (mL min–1)
1.04 1.07
extract flow rate (mL min–1)
protok ekstrakta (mL min–1)
1.02 1.17
zone I flow rate (mL min–1)
protok zone I (mL min–1)
5.91 6.22
zone II flow rate (mL min–1)
protok zone II (mL min–1)
4.90 5.06
zone III flow rate (mL min–1)
protok zone III (mL min–1)
5.40 5.56
zone IV flow rate (mL min–1)
protok zone IV (mL min–1)
4.36 4.49
eluent flow rate (mL min–1)
protok eluensa (mL min–1)
1.56 1.74
switch time (tact) (min)
vrijeme prespajanja (takt) (min)
2.53 2.41
extract purity (% ee)
èistoæa ekstrakta (% ee)
100 100
extract concentration (g L–1)
koncetracija ekstrakta (g L–1)
4.26 7.72
raffinate purity (% ee)
èistoæa rafinata (% ee)
99.9 100
raffinate mass concentration (g L–1)
masena koncetracija rafinata (g L–1)
3.05 7.05
productivity (mg L–1 h–1)
produktivnost (mg L–1 h–1)
2.96 
 104 3.91 
 104
eluent consumption (L g–1)
potrošak eluenta (L g–1)
0.48 0.27
panies are therefore introducing new concepts and tech-
nologies in R&D of new biologically active molecules, and
SMB technology to speed up the chemical part of these
projects.
4. Conclusion
This Part II of the review on SMB technology presents some
examples of the complex modification of the basic method-
ology, i. e. its combination with crystallization and biosyn-
thetic processes, and its modification into Varicol process,
characterized by continuous, virtual movement of both
ports and sections. The final section gives some numeric
data that reflect the high commercial importance of this
technology, in particular for development of new chiral
drugs in the pharmaceutical industry.
Finally, the intention of the authors was to familiarize the in-
terested reader with the characteristics of modern chemical
technology. First, SMB is characterized by intensive use of
specific software packages. Their development in the ex-
pert companies or modifications by users, as well as their
use in commercial form requires specific knowledge of the
chemist and chemical engineers. Beside, understanding of
sterochemical processes and characteristics of chiral mole-
cules are indispensable, as well as the knowledge of chro-
matographic processes and materials used in chiral chro-
matography. From all said, it is obvious that successful use
of SMB technology is a team enterprise, where all the mem-
bers, synthetic chemists, chromatographic experts and pro-
cess engineers, are expected to have up-dated knowledge
in the indicated fields of computational chemistry, ste-
reochemistry, chiral chromatography and chemical tech-
nology.
List of symbols
Popis smbola
d – diameter, cm
– promjer, cm
di – inside diameter, cm
– unutarnji promjer, cm
dp – particle diameter, nm
– promjer èestice, nm
l – length, cm
– duljina, cm
N – number of columns
– broj kolona
P – productivity, me.e mCSP
1 t–1, kg kg–1h–1
– produktivnost, me.e mCSP
1 t–1, kg kg–1h–1
p – pressure, bar
– tlak, bar
Q – volume flow rate, mL min–1
– obujamski protok, mL min–1
t – time, min, h, a
– vrijeme, min, h, a
Y – yield, %
– iskorištenje, %
g – mass concentration, g L–1
– masena koncentracija, g L–1
y – volume ratio, mL min–1
– obujamski omjer, mL min–1
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T a b l e 5 – Chiral leaders; nine of the top-10 drugs have
chiral active substance
T a b l i c a 5 – Kiralni voðe; devet od 10 vrhunskih lijekova
posjeduju kiralnu aktivnu tvar
Drug
Lijek
Global
2004
drug sale
($
billions)
Svjetska
prodaja
lijekova
u 2004.
(milijarde
$)
Active
substance
Aktivna tvar
Form of
active
substance
Oblik
aktivne
tvari
Therapeutic
class
Terapijska
skupina
Lipitor 12.0 atorvastatin single
enant.
jedini
enantiomer
cholesterol
reducer
snizuje
kolesterol
Zocor 5.9 simvastatin single
enant.
jedini
enantiomer
cholesterol
reducer
snizuje
kolesterol
Plavix 5.0 clopidogrel
klopidogrel
single
enant.
jedini
enantiomer
antithrombotic
antitrombotik
Nexium 4.8 esomeprazole
esomeprazol
single
enant.
jedini
enantiomer
antiulcerant
antiulcerant
Zyprexa 4.8 olanzapin achiral
akiral
antipsychotic
antipsihotik
Norvasc 4.8 amlodipin racemate
racemat
antihypertensive
antihipertenziv
Seretide 4.7 salmeterol racemate
racemat
bronchodilator
bronhodilator
fluticasone
flutikazon
single
enant.
jedini
enantiomer
antiinflammatory
protuupalni
Eripo 4.0 epoetin alpha
epoetin alfa
protein
protein
red blood cell
stim.
stimulator
crvenih krvnih
stanica
Ogastro 3.8 lansoprazol racemate
racemat
antiulcerant
antiulcerant
Effexor 3.7 venflaxin
venflaksin
racemate
racemat
antidepressant
antidepresiv
Total
Ukupno
53.5
Note: Sales figures from IMS Health
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SAÝETAK
Novija dostignuæa tehnologije simuliranog pokretnog leÞaja. II. Dio.
V. Šunjiæ,a* D. Franiæ,a D. Kontrecb i M. Rojeb
U prvom dijelu ovog pregleda prikazan je napredak metode simuliranog pokretnog leÞaja (SMB) i
neka vaÞnija dostignuæa u separaciji specifiènih skupina racemiènih spojeva od terapeutskog
znaèenja. U drugom dijelu ovog pregleda opisane su neke nove SMB tehnologije. Prikazane su
kompleksne tehnologije, kao što su kombinacija SMB-a i biokatalitièkih reakcija te kombinacija
SMB-a i procesa kristalizacije. Raspravlja se varijanta VariCol SMB-a i njezina primjena u separa-
ciji racemiènih smjesa od komercijalnog i akademskog interesa. U zakljuènom dijelu komentira
se znaèenje ekonomske dimenzije i trÞišta enantiomerno èistih spojeva.
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